Gilead Sciences, Inc. has announced that it has received new approval from the U.S. Food and Drug Administration (FDA) for a ...

An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent ...

Scientific breakthroughs take center stage at the International AIDS Society Conference as global HIV funding and political ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

The EU has approved lenacapavir, a twice-yearly HIV prevention shot that could replace daily pills, but experts say access ...

Scientists used a mRNA-based vaccine to reliably trigger antibodies that block HIV infection in people and monkeys ...

Resistance to ART was associated with poor clinical outcomes and increased economic burden in a national sample of veterans with HIV infection in the United States.

The global infectious disease treatment market is projected to grow from $72.5 billion in 2025 to $101 billion by 2030, with ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the preceding trading day.

The Supreme Court's Braidwood decision only concretized the power of the Department of Health and Human Services to decide what is necessary preventative care, rather than outright protecting ...